📊 ATOS Key Takeaways
Is Atossa Therapeutics, Inc.. (ATOS) a Good Investment?
Pre-revenue biopharmaceutical company with zero revenue and -$9.6M net loss in latest period. While balance sheet is strong with $31.7M cash and no debt providing ~3-4 years runway, ongoing cash burn with no product commercialization visibility creates significant execution risk. Company remains entirely dependent on successful drug development and commercialization for viability.
Atossa Therapeutics has a strong balance sheet with $51.84M of cash, no long-term debt, and very high liquidity, which supports continued clinical development without immediate financing pressure. However, the business remains pre-revenue and deeply unprofitable, with negative operating cash flow and no evidence yet of self-sustaining growth, so the fundamentals are financially stable but operationally speculative.
Atossa Therapeutics, Inc.. Key Strengths (ATOS)
- Strong cash position of $31.7M with zero long-term debt
- Excellent liquidity ratios (4.92x current ratio) provides operational flexibility
- Low liability burden ($7.5M) limits near-term financial distress risk
- Very strong liquidity with a 6.77x current and quick ratio
- Debt-free balance sheet with $49.79M of equity and no long-term debt
- Cash reserves cover multiple years of current operating cash burn
ATOS Stock Risks: Atossa Therapeutics, Inc.. Investment Risks
- Zero revenue with no clear path to commercialization or profitability
- Cash burn of -$9.6M per period with no offsetting revenue
- High development risk typical of pre-clinical/early-stage pharmaceutical companies
- Negative ROE (-31.5%) and ROA (-25.3%) reflect inefficient capital deployment
- Zero revenue means the business is entirely dependent on external capital and pipeline progress
- Persistent operating and net losses indicate weak profitability with no near-term earnings support
- Negative free cash flow and high cash burn could force dilution if development timelines extend
Key Metrics to Watch
- Monthly cash burn rate trend and projected runway
- Clinical trial progress and FDA milestone achievements
- Time to first revenue-generating product launch
- Quarterly operating cash burn relative to the $51.84M cash balance
- Any transition from zero revenue toward licensing, collaboration, or product revenue
Atossa Therapeutics, Inc.. (ATOS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.92x current ratio provides a solid financial cushion.
ATOS Profit Margin, ROE & Profitability Analysis
ATOS vs Healthcare Sector: How Atossa Therapeutics, Inc.. Compares
How Atossa Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Atossa Therapeutics, Inc.. Stock Overvalued? ATOS Valuation Analysis 2026
Based on fundamental analysis, Atossa Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Atossa Therapeutics, Inc.. Balance Sheet: ATOS Debt, Cash & Liquidity
ATOS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Atossa Therapeutics, Inc..'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-3.04 indicates the company is currently unprofitable.
ATOS Revenue Growth, EPS Growth & YoY Performance
ATOS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2016 | N/A | $204.7K | N/A |
| Q2 2016 | N/A | -$1.7M | N/A |
| Q1 2016 | N/A | -$2.3M | N/A |
| Q3 2015 | $3.4K | -$3.2M | N/A |
| Q2 2015 | $9.9K | -$3.1M | N/A |
| Q1 2015 | N/A | -$2.4M | N/A |
| Q3 2014 | N/A | -$3.2M | N/A |
| Q2 2014 | N/A | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Atossa Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
ATOS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Atossa Therapeutics, Inc.. (CIK: 0001488039)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATOS
What is the AI rating for ATOS?
Atossa Therapeutics, Inc.. (ATOS) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATOS's key strengths?
Claude: Strong cash position of $31.7M with zero long-term debt. Excellent liquidity ratios (4.92x current ratio) provides operational flexibility. ChatGPT: Very strong liquidity with a 6.77x current and quick ratio. Debt-free balance sheet with $49.79M of equity and no long-term debt.
What are the risks of investing in ATOS?
Claude: Zero revenue with no clear path to commercialization or profitability. Cash burn of -$9.6M per period with no offsetting revenue. ChatGPT: Zero revenue means the business is entirely dependent on external capital and pipeline progress. Persistent operating and net losses indicate weak profitability with no near-term earnings support.
What is ATOS's revenue and growth?
Atossa Therapeutics, Inc.. reported revenue of $0.0.
Does ATOS pay dividends?
Atossa Therapeutics, Inc.. does not currently pay dividends.
Where can I find ATOS SEC filings?
Official SEC filings for Atossa Therapeutics, Inc.. (CIK: 0001488039) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATOS's EPS?
Atossa Therapeutics, Inc.. has a diluted EPS of $-1.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ATOS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Atossa Therapeutics, Inc.. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ATOS stock overvalued or undervalued?
Valuation metrics for ATOS: ROE of -31.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ATOS's AI grade for 2026?
Our dual AI analysis gives Atossa Therapeutics, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ATOS's free cash flow?
Atossa Therapeutics, Inc..'s operating cash flow is $-9.6M, with capital expenditures of $0.0.
How does ATOS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -31.5% (avg: 15%), current ratio 4.92 (avg: 2).